Biogen is bolstering the company’s multiple sclerosis pipeline through a licensing agreement with Maine-based MedRhythms for its investigational digital therapeutic MR-004, which is being assessed for the potential treatment of gait deficits in MS.
Roche warned that Russia’s attack on Ukraine is disrupting the development of a new generation of multiple sclerosis (MS) drugs as the industry has come to disproportionately rely on Eastern Europe for clinical trials.
Teva Pharmaceutical Industries forecast lower revenue and profit for 2019, missing analysts’ expectations, as the company faces generic competition for two key branded drugs.
Denali announced a collaborative deal with Sanofi to develop potential treatments for neurological and systemic inflammatory diseases that could be worth more than $1 billion.
Active Biotech regained the global development and commercialization rights to the neurodegenerative disease drug laquinimod from Teva Pharmaceutical Industries.
2016 was not a banner year for M&A in the biopharma industry compared to 2014 and 2015. BioPharmaDIVE looks at seven potential acquisition targets for 2017.
A potential miracle drug developed by Biogen failed to meet the endpoints of a Phase II clinical trial.
Biogen Inc.’s keenly watched experimental drug for treating multiple sclerosis failed to meet the main goal of improving some symptoms in a mid-stage study.
A once-per-month injection for MS developed by Biogen and AbbVie received FDA approval.
After the announcement by Biogen that it was spinning off its hemophilia business, analysts and investors are pondering, somewhat quizzically, just what it means.